首页|精氨酸布洛芬颗粒在中国健康受试者中的生物等效性研究

精氨酸布洛芬颗粒在中国健康受试者中的生物等效性研究

扫码查看
目的 评价精氨酸布洛芬颗粒受试制剂和参比制剂在中国健康受试者中空腹和餐后状态下的生物等效性和安全性,为该药的一致性评价和临床应用提供依据.方法 采用单中心、单剂量、随机、开放、空腹和餐后、两周期、两交叉试验设计,空腹与餐后试验各纳入中国成年健康受试者24例,随机交叉单次口服精氨酸布洛芬颗粒受试制剂和参比制剂各0.4 g,按时间点采血后,用高效液相色谱-质谱联用法进行血药浓度检测,用Phoenix WinNonlin 8.3进行数据分析.结果 空腹组受试者服用精氨酸布洛芬颗粒受试制剂和参比制剂后,血浆中布洛芬主要药代动力学参数如下:Cmax分别为(51.07±7.43)和(50.10±7.64)μg·mL-1,AUC0-t分别为(122.78±20.62)和(119.94±21.03)μg·h·mL-1,AUC0-∞ 分别为(125.84±21.31)和(122.64±21.87)μg·h·mL-1;餐后组受试者服用精氨酸布洛芬颗粒受试制剂和参比制剂后,血浆中布洛芬主要药代动力学参数如 下:Cmax 分别为(17.47±3.56)和(17.89±4.47)μg·mL-1,AUC0-t 分别为(114.33±17.12)和(122.13±29.46)μg·h·mL-1,AUC0-∞分别为(134.04±36.72)和(133.96±30.35)μg·h·mL-1.两制剂几何均值比的90%置信区间如下:空腹组Cmax97.96%~106.02%、AUC0-t 98.77%~105.14%、AUC0-∞ 99.34%~105.19%;餐后组 Cmax 92.37%~103.05%、AUC0-t 93.31%~99.56%、AUC0-∞ 93.89%~102.91%.结论 本研究中精氨酸布洛芬颗粒的受试制剂和参比制剂在中国健康成年受试者中具有生物等效性.
Bioequivalence of ibuprofen arginine granules in healthy Chinese volunteers
Objective To evaluate the bioequivalence and safety of ibuprofen arginine granules test and reference formulations in Chinese healthy volunteers under fasting and postprandial conditions,and to provide evidence for consistency evaluation and clinical application of the drugs.Methods A single-center,single-dose,randomized,open-label,fasting and postprandial,two-period,two-crossover trial design was used.Twenty-four healthy Chinese volunteers were enrolled in the fasting and postprandial trial,respectively.The test preparation and reference preparation of ibuprofen arginine granules 0.4 g were taken orally in a randomized crossover single dose.Data analysis was performed using Phoenix WinNonlin 8.3.Results In the fasting group,the main pharmacokinetic parameters of ibuprofen in plasma after administration of the test and reference formulations of ibuprofen arginine granules were as follows:Cmax were(51.07±7.43)and(50.10±7.64)μg·mL-1;AUC0-,were(122.78±20.62)and(119.94±21.03)μg·h·mL-1;AUC0_∞ were(125.84±21.31)and(122.64±21.87)μg·h·mL-1,respectively.In the postprandial group,the main pharmacokinetic parameters of ibuprofen in plasma after administration of the test and reference formulations of ibuprofen arginine granules were as follows:Cmax were(17.47±3.56)and(17.89±4.47)μg·mL-1;AUC0-twere(114.33±17.12)and(122.13±29.46)μg·h·mL-1;AUC0_∞ were(134.04±36.72)and(133.96±30.35)μg·h·mL-1,respectively.The 90%confidence intervals of the geometric mean ratio of the two preparations were as follows:Cmax 97.96%-106.02%,AUC0_t 98.77%-105.14%,AUC0-∞ 99.34%-105.19%in fasting group;in postprandial group,Cmax was 92.37%-103.05%,AUC0-t was 93.31%-99.56%,AUC0-∞ was 93.89%-102.91%.Conclusion The test preparation and reference preparation of ibuprofen arginine granules in this study are bioequivalent in healthy adult Chinese volunteers.

ibuprofen arginine granuleshealthy volunteerspharmacokinetichigh performance liquid chromatography-mass spectrometry(HPLC-MS/MS)bioequivalence

石盼盼、沈芬、宋丽梅、赵丰丽、李望、张伟臣、田禹

展开 >

山西省运城市中心医院药物临床试验中心,山西运城 044000

海南葫芦娃药业集团股份有限公司,海南海口 570000

精氨酸布洛芬 健康受试者 药代动力学 高效液相色谱-质谱联用法 生物等效性

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(1)
  • 1